FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website
horizonal rule
Dockets Management


RPT 280
Volume 217

Cover Page

Letter from CFSAN to W. Patrick Noonan

Letter from W. Patrick Noonan to CFSAN

Table of Contents

Section 1 - Names and complete addresses of the distributor and manufacturer of the new dietary ingredient

Section 2 - Name of the new dietary ingredient

Section 3 - Description of the new dietary ingredient

Section 4 - Level of the new dietary ingredient in the dietary supplement

Section 5 - The conditions of use recommended or suggested in the labeling of the dietary supplement

Section 6 - History of use or other evidence of safety establishing that the dietary ingredient Zeaxanthin Purified Concentrate as recommended in the labeling of dietary supplement

Attachment 1 - Zeaxanthin production process

Attachment 2 - Zeaxanthin Purified Concentrate (ZPC) proximate analysis

Attachment 3 - Report of Analysis, Final Report, Certificate of Analysis

Attachment 4 - Chrysantis material data safety sheet for ZPC

Attachment 5-12 Published Material

Attachment 13 - Joint FAO/WHO Expert Committee on Food Additives (JECFA) Sixty-Third Meeting, Geneva, 8-17, June 2004

Attachment 14-25 Published Material

Attachment 26 - Statement of safety for zeaxanthin when used as a dietary supplement in a water B soluble beadlet formulatio at a level of up to 10mg/person/day. Prepared for ZeaVision, LLP, by Dennis Giehart, Ph.D., March 12, 2002.

Attachment 27-30 Published Material

Section 7 - Summary


Top | Back

Page last updated August 4, 2005 RSChorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management